{Reference Type}: Journal Article
{Title}: [Impact on quality of life and autonomy of patients aged over 75 years treated with anti-PD-1 for metastatic melanoma: A single-centre prospective study].
{Author}: Barailler H;Dousset L;Mertens C;Maurel A;Gérard E;Prey S;Dutriaux C;Beylot-Barry M;Pham-Ledard A;
{Journal}: Ann Dermatol Venereol
{Volume}: 147
{Issue}: 11
{Year}: Nov 2020
{Factor}: 0.934
{DOI}: 10.1016/j.annder.2020.07.012
{Abstract}: <B>BACKGROUND: </B>We previously studied anti-PD-1 safety in elderly (≥80 years) patients and reported a retrospective two-centre cohort with a similar safety profile in elderly and in younger patients. Quality-of-life evaluation data is still lacking in this specific population.<BR><B>METHODS: </B>A prospective, single-centre study in patients aged over 75 years presenting metastatic melanoma treated with anti-PD-1. The endpoint was monitoring of quality of life (by a specific survey) and onco-geriatric assessment at the beginning of therapy, then at 3 and 6 months (nutritional status, comorbidities, autonomy, thymic and cognitive disorders).<BR><B>RESULTS: </B>Fourteen patients were included of median age 86.5 years [range: 78-94] from March to September 2018. General status was good, with a median Charlson score of 0 [extremes 0-4]. Nine patients were evaluated at 3 months and six patients at 6 months. There was no significant difference in quality-of-life scores obtained at baseline, 3 months and 6 months.<BR><B>CONCLUSIONS: </B>This study shows that neither quality of life nor autonomy appears to be affected by anti-PD-1 treatment in patients aged over 75 years. However, these results should be interpreted with caution due to the small number of patients included, the short follow-up period and the single-centre data. Nevertheless, the prospective analysis and the complete onco-geriatric evaluation and monitoring yielded unique and original data.